Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT03802604||Recruiting||Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer||
||Early Phase 1||
||Other / Industry||
||30||Female||18 Years to 99 Years (Adult, Older Adult)||NCT03802604||SOLTI-1503||PROMETEO||December 10, 2018||November 2020||November 2023||January 14, 2019||January 21, 2019||